Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

BERWYN, Pa., July 27, 2020 /PRNewswire/ -- RM LAW, P.C.

RM LAW Announces Investigation of Vaxart, Inc.

NEW YORK, July 27, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT).

Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Vaxart, Inc.

The Law Offices of Frank R. Cruz Announces Investigation of Vaxart, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)---- $VXRT #fraud--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Vaxart, Inc.

NEW YORK, July 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential claims on behalf of shareholders of Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT) arising from allegations that Vaxart's Board of Directors may.

VXRT SHAREHOLDER INVESTIGATION: Bernstein Liebhard Announces an Investigation into Vaxart, Inc., and Encourages Investors to Contact the Firm

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Vaxart, Inc. (NASDAQ: VXRT) for violations of federal securities laws.

VXRT Alert: Johnson Fistel Launches Investigation into Vaxart, Inc. - Investors Suffering Losses Encouraged to Contact Firm

Co-Diagnostics

Novavax

These stocks have delivered gains of 2,300% and more. But could they go even higher?

3 Best-Performing Coronavirus Stocks of 2020 So Far: Are They Buys Now?

BioNTech SE

Inovio Pharmaceuticals

Moderna

COVID-19 vaccines might not be the moneymakers investors are hoping for.

Why Moderna, Vaxart, Inovio, and BioNTech Stocks Dropped Today

Sorrento Therapeutics Inc

Which stock wins in a matchup between these clinical-stage biotechs?

Better Coronavirus Stock: Sorrento Therapeutics vs. Vaxart

AstraZeneca

Johnson & Johnson

Pfizer

The U.S. government is pouring money into coronavirus vaccine development, and a handful of companies are cashing in.

Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator

Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.

3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data

Some of the companies pursuing a coronavirus vaccine will end up far more valuable than they are today -- while others might be a disaster waiting to happen.

Beware! Your Coronavirus Stock Might Be Crushed by the FDA

Both biotechs have been huge winners so far this year. One seems more likely to keep on winning.

Coronavirus Vaccine Race: Novavax or Vaxart?

Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.

Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress

Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%

These three vaccine stocks show no signs of slowing down their breathtaking pace of growth.

3 Game-Changing Coronavirus Vaccine Stocks That May Make You Rich

Over 90% of norovirus' total annual cost is due to sporadic spread in the community. Over 90% of norovirus' total annual cost is due to sporadic spread in the community.

Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States

Both Moderna and Vaxart are expecting data readouts that will send the stocks skyrocketing -- if the news is positive.

These 2 Coronavirus Stocks Could Soar in the Second Half of 2020

Investors are growing increasingly bullish on the coronavirus vaccine maker's growth prospects.

Why Vaxart Stock Soared 40% Today

Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.

Why Vaxart's Stock Is Trading Higher Today

RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock

Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility

As a small and scrappy competitor in the COVID-19 vaccine race, Vaxart is a lucrative opportunity for investors of all stripes.

Everything You Need to Know About Vaxart and Its Potential Coronavirus Vaccine

Both companies are developing new types of vaccines. The risk is high -- but so is potential for share performance.

Coronavirus Vaccine Race: Moderna or Vaxart?

Altimmune

Both of these small-cap vaccine stocks are up big in 2020.

Better Coronavirus Stock: Altimmune vs. Vaxart

VBI Vaccines

There's more to these small biotechs than just their coronavirus vaccine programs.

News for Vaxart Stock (VXRT)